Kim Oakhill Seeks £150,000 for Private Lung Cancer Drug After Stage 4 Diagnosis
Updated
Updated · The Mirror · May 28
Kim Oakhill Seeks £150,000 for Private Lung Cancer Drug After Stage 4 Diagnosis
1 articles · Updated · The Mirror · May 28
£150,000 is being raised by Kim Oakhill, 51, for a private targeted lung cancer drug after she was told the treatment is unavailable on the NHS.
Stage 4 lung cancer was found only after months of symptoms first treated as perimenopause, then as infections, asthma and acid reflux, before a CT scan revealed a mass on her right lung.
The cancer had already spread to the lining of her heart and brain, leaving it advanced and inoperable; after intensive chemotherapy ended in April, she was told the NHS would have nothing further to offer once it spread again.
Ely-based Oakhill, a mother of three who said she has never smoked, is also using her case to challenge the stigma that lung cancer affects only smokers.
When life-saving drugs are privately funded, is crowdfunding creating a two-tier system for UK cancer survival?
Her cancer was mistaken for menopause. How many other women's fatal symptoms are being dismissed by doctors today?
From Misdiagnosis to Mobilization: Kim Oakhill’s Stage 4 Lung Cancer Battle and the Systemic Gaps in UK Cancer Care
Overview
Kim Oakhill, once fit and healthy, is now fighting stage 4 non-small cell lung cancer after her symptoms—like extreme fatigue, night sweats, poor sleep, and leg pain—were first mistaken for perimenopause. This delay in diagnosis has made her need for advanced, life-extending treatment urgent. The main hope lies in Antibody-Drug Conjugates (ADCs), which use monoclonal antibodies to deliver powerful drugs directly to cancer cells. ADCs have shown real improvements in survival and response rates for patients. Kim’s story highlights the importance of timely diagnosis and access to innovative therapies for those facing critical illness.